Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:01 2024-07-05 EDT			5-day change	1st Jan Change
1.875 ^USD	+6.52%		+2.45%	+4.45%

05-14	Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-08	Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board	CI

Eterna Therapeutics Inc. Announces the Resignation of Roger Sidhu as Chief Medical Officer, Effective on January 31, 2023

January 26, 2023 at 04:32 pm

On January 20, 2023, Dr. Roger Sidhu, Chief Medical Officer of Eterna Therapeutics Inc., a Delaware corporation, delivered his notice of resignation, with such resignation becoming effective on January 31, 2023.

Latest news about Eterna Therapeutics Inc.

Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board	05-08	CI
Eterna Therapeutics Inc. to Present at the ASGCT 27Th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line	05-07	CI
North American Morning Briefing : Inflation -2-	03-15	DJ
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors	02-20	CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee	02-16	CI
Eterna Therapeutics Inc. Announces Management Changes	01-19	CI
Eterna Therapeutics Inc Announces Chief Executive Officer Changes, Effective January 1, 2024	12-20	CI
Eterna Therapeutics Inc Appoints Sanjeev Luther as President and Member of the Board of Directors, Effective January 1, 2024	12-20	CI
Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board	12-20	CI
Eterna Therapeutics Selling $9.2 Million of Convertible Promissory Notes, Accompanying Warrants	12-15	MT
Eterna Therapeutics Inc. announced that it expects to receive $9.2 million in funding	12-13	CI
Eterna Therapeutics Inc. announced that it has received $1.5 million in funding	12-07	CI
Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited	11-16	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Eterna Therapeutics Inc. Appoints James Bristol to Its Board of Directors	11-01	CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30	MT
Gregory Fiore Resigns from Eterna Therapeutics Inc.'s Board of Directors	23-10-05	CI
Lineage Cell Therapeutics, Inc. Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics	23-09-06	CI
Eterna Therapeutics Inc. Appoints Ms. Dorothy J. Clarke as Director, Effective on August 28, 2023	23-08-31	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Eterna Therapeutics Inc. Announces Management Changes	23-08-10	CI
Eterna Therapeutics Inc. announced that it has received $8.715 million in funding	23-07-12	CI
Eterna Therapeutics Inc. Announces Board Changes	23-07-11	CI

Chart Eterna Therapeutics Inc.

Duration

Period

More charts

Company Profile

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
ETERNA THERAPEUTICS INC.	+4.45%	10.14M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research